Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Claudin 18.2xCD3 bispecific antibody - Genor Biopharma, GB 264, GB-264 |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Carcinoma | Preclinical | US | 06 Aug 2021 | |
Pancreatic Carcinoma | Preclinical | CN | 06 Aug 2021 | |
Gastrointestinal Neoplasms | Preclinical | CN | - |